anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Critically ill patients are at risk of suboptimal beta-lactam antibiotic (beta-lactam) exposure due to the impact of altered physiology on pharmacokinetics. Suboptimal concentrations can lead to treatment failure or toxicity. Therapeutic drug monitoring (TDM) involves adjusting doses based on measured plasma concentrations and individualising dosing to improve the likelihood of improving exposure. Despite its potential benefits, its adoption has been slow, and data on implementation, dose adaptation and safety are sparse. The aim of this trial is to assess the feasibility and fidelity of implementing beta-lactam TDM-guided dosing in the intensive care unit setting.
METHODS AND ANALYSIS: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring (ADAPT-TDM) is a single-centre, unblinded, feasibility randomised controlled trial aiming to enroll up to 60 critically ill adult participants (≥18 years). TDM and dose adjustment will be performed daily in the intervention group; the standard of care group will undergo plasma sampling, but no dose adjustment. The main outcomes include: (1) feasibility of recruitment, defined as the number of participants who are recruited from a pool of eligible participants, and (2) fidelity of TDM, defined as the degree to which TDM as a test is delivered as intended, from accurate sample collection, sample processing to result availability. Secondary outcomes include target attainment, uptake of TDM-guided dosing and incidence of neurotoxicity, hepatotoxicity and nephrotoxicity.
ETHICS AND DISSEMINATION: This study has been approved by the Alfred Hospital human research ethics committee, Office of Ethics and Research Governance (reference: Project No. 565/22; date of approval: 22/11/2022). Prospective consent will be obtained and the study will be conducted in accordance with the Declaration of Helsinki. The finalised manuscript, including aggregate data, will be submitted for publication in a peer reviewed journal. ADAPT-TDM will determine whether beta-lactam TDM-guided dose adaptation is reproducible and feasible and provide important information required to implement this intervention in a phase III trial.
TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry, ACTRN12623000032651.
Postamputation pain is a common condition in patients with lower limb amputation (LLA), which compromises amputees' rehabilitation, use of the prosthesis, and quality of life. The aim of our study was to investigate the prevalence of phantom limb pain (PLP), residual limb pain (RLP), or both types of pain among individuals with LLA, and to identify the factors associated with the presence of one type of pain versus the other. Patients who underwent amputation for traumatic or vascular reasons and who reported on RLP or PLP were analyzed and divided into three groups: PLP, RLP, or a group of subjects that presented both pains. We searched for factors that affect the occurrence of limb pain using univariate analyses, followed by multinomial logistic regression. Among the 282 participants with transtibial and transfemoral amputations, 192 participants (150 male and 42 female) presented PLP, RLP, or both types of pain, while 90 participants declared to perceive no pain. The estimated prevalence of any type of pain after transfemoral and transtibial amputation was therefore 68% (27% PLP, 10% RLP, and 31% both). Among the studied characteristics, only amputation level was associated with the type of pain ( P  = 0.001). Multinomial logistic regression identified transfemoral amputation as the only statistically significant predictor for PLP (odds ratio = 2.8; P  = 0.002). Hence, it was estimated that individuals with transfemoral amputation have nearly three times higher odds of experiencing PLP compared with those with transtibial amputation.
Disruption of the hypothalamic-pituitary axis due to congenital abnormalities, tumors or head trauma may cause anterior and/or posterior pituitary deficiency also known as partial or panhypopituitarism. Patients with hypopituitarism, especially those with panhypopituitarism (i.e., anterior and posterior insufficiency) often report residual symptoms and lower quality of life despite adequate substitution treatment of deficient pituitary hormones. A recent study identified a potential oxytocin deficient state in men with combined anterior and posterior deficiency. Due to the close proximity of vasopressin and oxytocin, disruption of the vasopressin system leading to diabetes insipidus could as well disturb the oxytocin system leading to low oxytocin levels. It is therefore possible that the increased psychopathology and reduced quality of life as observed in patients with central diabetes insipidus is caused by an oxytocin deficiency. Several studies documented marked acute increases in circulating oxytocin levels in response to 3,4-methylenedioxymethamphetamine (MDMA) administration as compared to placebo in healthy volunteers.

MDMA could therefore be useful as a provocation test to detect an oxytocin deficiency in patients with central diabetes insipidus. This study is to investigate if oxytocin provocation following a single dose administration of MDMA is reduced in patients with central diabetes insipidus as compared to healthy volunteers.
PURPOSE:To obtain the titled factor capable of exhibiting the diminishing action specifically on only human cancerous cells, by dialyzing a culture fluid of a human fetal fibroblast against water, and adsorbing the dialyzate on an adsorbent under acidic conditions, extracting the adsorbed dialyzate with an aqeuous alkaline solution, heat-treating the resultant adsorbed extract, and subjecting the heat-treated extract to the gel filtration. CONSTITUTION:A human fetal fibroblast is cultivated, and a culture fluid is collected when the fibroblast is spread over the whole surface of the cultivation wall. The culture fluid is then filtered to remove insoluble foreign materials, and the resultant filtrate is fully dialyzed against water. The resultant inner dialyzate is acidified and brought into contact with a suitable adsorbent, e.g. kaolin or bentonite, to adsorb active constituents thereon. The active constituents are then extracted from the adsorbent with a weak alkaline aqueous solution, e.g. aqueous ammonia, and the above-mentioned extract solution is neutralized, heat-treated (at 60- 80 deg.C for 30-90min) and then subjected to the gel filtration to give the aimed human tumorous cell degeneration factor (TDF). In the above-mentioned cultivation, the TDF is produced in a high concentration by mixing the fibroblast with a human epithelial cancerous cell, and cultivating the resultant mixture. The diminishing action of the TDF on cancerous cells is enhanced by human leukocytic interferon.
Deactivation of the medial prefrontal cortex (mPFC) has been broadly reported in both neuropathic pain models and human chronic pain patients. Several cellular mechanisms may contribute to the inhibition of mPFC activity, including enhanced GABAergic inhibition. The functional effect of GABAA(γ-aminobutyric acid type A)-receptor activation depends on the concentration of intracellular chloride in the postsynaptic neuron, which is mainly regulated by the activity of Na-K-2Cl cotransporter isoform 1 (NKCC1) and K-Cl cotransporter isoform 2 (KCC2), 2 potassium-chloride cotransporters that import and extrude chloride, respectively. Recent work has shown that the NKCC1-KCC2 ratio is affected in numerous pathological conditions, and we hypothesized that it may contribute to the alteration of mPFC function in neuropathic pain. We used quantitative in situ hybridization to assess the level of expression of NKCC1 and KCC2 in the mPFC of a mouse model of neuropathic pain (spared nerve injury), and we found that KCC2 transcript is increased in the mPFC of spared nerve injury mice while NKCC1 is not affected. Perforated patch recordings further showed that this results in the hypernegative reversal potential of the GABAA current in pyramidal neurons of the mPFC. Computational simulations suggested that this change in GABAA reversal potential is sufficient to significantly reduce the overall activity of the cortical network. Thus, our results identify a novel pathological modulation of GABAA function and a new mechanism by which mPFC function is inhibited in neuropathic pain. Our data also help explain previous findings showing that activation of mPFC interneurons has proalgesic effect in neuropathic, but not in control conditions. PERSPECTIVE: Chronic pain is associated with the presence of depolarizing GABAA current in the spinal cord, suggesting that pharmacological NKCC1 antagonism has analgesic effects. However, our results show that in neuropathic pain, GABAA current is actually hyperinhibitory in the mPFC, where it contributes to the mPFC functional deactivation. This suggests caution in the use of NKCC1 antagonism to treat pain.
PROBLEM TO BE SOLVED: To provide a cosmetic composition for keratin fibers, the composition having less bad smell and also having strong decoloring power.SOLUTION: A cosmetic composition for keratin fibers can be obtained from a mixture of an alkali-containing composition containing at least one kind of alkali agent and at least one kind of surfactant, and an oxidation composition containing at least one kind of oxidant and at least one kind of fat substance. The amount of the fat substance in the alkali-containing composition is 10-50 mass%, preferably 20-40 mass% to the total mass of the oxidation composition. In the cosmetic composition for keratin fibers, at least one kind of polyol is contained at 0.1-40 mass%, preferably 0.5-30 mass% to the total mass of the cosmetic composition for keratin fibers. In the cosmetic composition for keratin fibers, at least one kind of surfactant is contained at 15-30 mass% to the total mass of the cosmetic composition for keratin fibers. In the cosmetic composition for keratin fibers, at least one kind of fat substance is contained at 5-30 mass% to the total mass of the cosmetic composition for keratin fibers. The mass ratio of the surfactant versus fat substance in the cosmetic composition for keratin fibers is 0.3 to 2.0, preferably 0.7 to 1.3.SELECTED DRAWING: None
The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in children and adults.

In reality, targeted antimicrobial therapy can most effectively be achieved by utilizing personalized data to facilitate a tailored and optimized approach to individual patient treatment. This can best be achieved by utilizing knowledge gained from both host-centered and pathogen-centered parameters during health and disease. Unfortunately, these parameters have traditionally, tended to be measured independently (for example using microbial culture or PCR-based methods for microbial detection, or measurement of the immune response to infections and/or blood-based biomarkers in the host), and used on an ad hoc basis without careful integration for the best treatment of the patient. However, recent advances in the development of high-throughput and sensitive molecular-based technologies, on-line internet database access tools, and bioinformatics analysis, now means that the goal of personalized medicine and treatment is in sight. Unfortunately however, there currently exists a technological gap between recent state-of-the-art methodologies (for example with respect to gaining new insights into novel host-pathogen interactions) and laboratory-to-bedside results to benefit patients, physicians and society as a whole. The TAILORED-Treatment project is designed to bridge this technological gap in order to generate novel insights and innovations that are readily exploitable for the maximum benefit of multiple stakeholders in the field of personalized medicine and infectious diseases.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to stable peroral pharmaceutical composition and to its preparation where alterations of medicinal agent releasing are prevented at storage under conditions of light effect by addition of yellow ferric (III) oxide and/or red ferric (III) oxide to the preparation with prolonged release of matrix type and comprising medicinal agent, hydrophilic base and polyethylene oxide. Invention relates also to method for prevention of alterations in releasing medicinal agent at storage of preparation with prolonged release of matrix type and comprising medicinal agent, hydrophilic base and polyethylene oxide under conditions of light effect. Invention provides increasing the guaranteed time for product storage and to enhance quality of product. EFFECT: improved preparing method, valuable pharmaceutical properties of composition. 21 cl, 1 tbl
Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion. and cervical muscle METs.
Depression is a widespread disease, with high mortality and recurrence rates. Recent studies have shown that elevated cytokine levels are implicated in the molecular mechanisms of depression. Oxidative stress contributes to the stimulation of cytokine production. Growing evidence suggests that ginsenoside Re (Gs-Re) exerts a neuroprotective effect on the hippocampus by suppressing oxidative stress and inflammation. However, the effect and mechanism of Gs-Re in the treatment of depression remain understudied. This study aimed to evaluate the neuroprotective and antidepressant-like effects of Gs-Re and the possible underlying mechanisms. In this article, the antidepressant-like effect of the Gs-Re was studied both in vitro (H2O2-induced oxidative stress in HT-22 cells) and in vivo (reserpine-induced depressive model mice). Our results indicated that, at the cellular level, Gs-Re effectively enhanced cell survival following H2O2 stimulation, inhibited the mass production of oxidative stress markers (MDA and ROS), and prevented the occurrence of apoptosis. Moreover, Gs-Re significantly reduced the levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α and restored the abnormal mitochondrial membrane potential. Subsequently, Gs-Re treatment reversed reserpine-induced neuroinflammation and depressive-like behaviors in vivo and inhibited microglia overactivation. Furthermore, the alterations in the BDNF/TrkB/ERK/CREB signaling pathway induced by H2O2 or reserpine in HT-22 cells or in the mouse hippocampus were significantly reversed by Gs-Re. K252a blocked the improvement of Gs-Re on depression-like behavior and eliminated the inhibition of oxidative stress and neuroinflammation in vivo. This study suggested that Gs-Re produces neuroprotective and depressive effects by inhibiting oxidative stress and inflammation and activating the BDNF/TrkB/ERK/CREB pathway.
Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
FIELD: organic chemistry, steroids, pharmacy. SUBSTANCE: invention relates to analogs of vitamin D 3  of the general formula (I)   where R 1  and R 2  - hydrogen or acyl-group under condition that one of these groups R 1  or R 2  means hydrogen. Compounds are synthesized by photolysis of compound of the formula (II)   using 4-dialkylaminobenzoate, in part, 4-dimethylaminobenzoate as a filter that blocks light at wavelength 290-320 nm. Invention relates to also a pharmaceutical composition based on compounds of the formula (I) that can be used for treatment of patients with hyperproliferative skin sicknesses, for example, psoriasis, acnes and seborrhea eczema. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 6 cl, 5 tbl
A live attenuated human immunodeficiency virus type 1 (HIV-1) whose replication is not constitutive but is instead conditionally regulated (such that rounds of reverse transcription with accompanying potential for error are strictly limited) might yield a paradigm that minimizes evolution to virulence and facilitate vaccine development. We have broached the concept of conditional control of HIV-1 through gain-of-function. Here, we describe the design of constitutively inactive HIV-1 genomes (HIV-DoxT and HIV-DoxSp) which can be conditionally resuscitated to an active state by tetracycline or related analogues. The HIV-DoxT construct comprises an inactivating mutation engineered into TAR, thereby rendering the virus non-responsive to Tat, a 302-bp DNA fragment (TetopT) which contains the tet-operator ligated into a position upstream of the HIV TATAA box, in both the 5' and 3' LTRs, and a reverse tetracycline-controlled activator (RTTA) coding sequence in place of the nef coding region. The HIV-DoxSp construct contains three additional Sp1 sites in the TetopT promoter upstream of the TATAA box thereby generating the promoter TetopSp. Genotypically, HIVDoxT is tat(+)tar(-)nef(-)Sp1(-) and HIVDoxSp is tat(+)tar(-)nef(-)Sp1(+). Since both genomes are genetically tar(-), they would ordinarily be expected to be wholly defective in producing viral proteins and/or particles. However, following transfection into an appropriate cell target, both proviruses, in a doxycycline-dependent fashion, capably released Gag and RT from cells. In the absence of doxycycline, no replication competent virus could be recovered. These findings suggest that the heterologous RTTA+Dox mechanism substituted effectively for Tat/TAR. These constructs should prove useful in the development of HIV-specific immunological and diagnostic reagents.
FIELD: transfusion techniques and epidemiology. SUBSTANCE: biological material is centrifuged to precipitate ballast substances and then cellular and viral precipitate of biological material is lysed. Viral, bacterial, and cellular DNA and RNA are precipitated by isopropyl alcohol and transferred from organic medium into dry precipitate, which is treated by reverse transcriptase in buffer, containing triple-substituted phosphates and primers for RNA, to give summary DNA and cDNA preparation for precipitation assays avoiding isolation of RNA. Precipitation assay is carried out by mixing DNA preparation with preliminarily prepared reagents: double buffer with enzyme Taq polymerase and gene amplification reagent specific for each infection agent and analyzed gene, which contains primers and triple-substituted phosphates. Reagent kits are used for diagnosing hepatitis B and C, HIV infections and lues enabling detection of several infections in the same sample. EFFECT: facilitated infection diagnostics. 12 cl, 8 dwg, 7 ex
Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
Participants will receive an intro to TRE and then throughout 8 weeks they will receive brief online psychoeducation several times per week with optional weekly coaching sessions. TRE involves restricting the window of eating to 10 hours/ day, most typically by avoiding eating in the first 1-2 hours after awakening and in the 2-4 before sleep. Those with an eating window \> 14 hours will be asked to restrict their eating to 12 hours in the first week, then 10 hours in week 2. To select the period, investigators will ask Ss to review baseline logs to consider sleep, eating, family meals and social commitment schedules, and any special energy demands, such as exercise. During the eating window, no restrictions are placed on the type or quantity of food consumed. The investigators will instruct participants to follow their habitual diet within their 10-hour eating window and to aim to consume the same number of calories per day as they did at baseline.
This study is a micro-trial of our mindful yoga intervention, BEING, tailored to the MAT clients. This study adapts an existing manualized program of yoga and mindfulness intervention (BEING) for MAT participants. Particularly important is addressing potential challenges and concerns regarding acceptability and feasibility of implementation in vulnerable males with substance dependence. We are enlisting the support of a mindful yoga expert with experience in related populations (i.e., previously incarcerated male veterans with mental health issues) in the adaptation process. This study is designed primarily to test the feasibility of the implementation of the intervention. We cannot draw statistically valid conclusions about the impact the intervention on outcomes, given the overall study design. We plan to collect participant feedback on whether or not the intervention is acceptable. We also want to evaluate the availability, accessibility, acceptability and feasibility of collecting certain measures that would be collected in a subsequent adequately powered treatment study.
A material capsule containing a reactive or caustic dental material and a separately attachable delivery tip having a metal cannula. A material capsule for placement in a syringe contains a reactive or caustic dental material for dispensing through a metal cannula. The material capsule is sealed for storing the caustic or reactive dental material, preventing prolonged contact with or proximity to the metal cannula of a delivery tip. Contact with the reactive or caustic dental material only occurs during actual dispensing. Transition portions facilitate dispensing of viscous material. External grips facilitate attachment of the delivery tip. The dispensing and accurate placement of caustic or reactive dental materials is facilitated, making dentistry easier.
Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.
The present study was planned as prospective analysis with 12-month follow-up. It enrolled 12 partially edentulous patients (mean age 62; range 42-86) requiring vestibular soft tissue augmentation at implant sites in second-stage surgery because of mild horizontal ridge deficiency. As a whole, 16 implants were placed (8 single, 4 dual).